Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

IVE Group - FY23 Results Presentation (ASX:IGL)

To view the presentation, download the attached PDF.

IVE Group - Financial Results for the Year Ending 30 June 2023 (ASX:IGL)

Financial results for the Year Ending 30 June 2023 IVE Group Limited (IVE, the Company or the Group) is pleased to announce its financial results for the 12 months ended 30 June 2023 (FY23). T...read more

icetana investor webinar presentation (ASX:ICE)

icetana Limited (ASX:ICE “icetana” or “the Company”) is pleased to announce its participation in the ShareCafe SmallCap "Hidden Gems" Webinar, to be held Friday 11t...read more

icetana - investor presentation (ASX:ICE)

To view the presentation, download the attached PDF.

INOVIQ - EXO-OC Program Completes Serum Equivalence Study (ASX:IIQ)

Serum equivalence study confirms EXO-NET isolates extracellular vesicles (EVs) from both plasma and serum samples- enables access to large ovarian cancer serum biobanks for further research ...read more

Immutep receives positive scientific advice from EMA (ASX:IMM)

SYDNEY, AUSTRALIA – 1 August 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel ...read more

INOVIQ - INOVIQ Investor Briefing (ASX:IIQ)

To view the Investor Briefing, download the attached PDF.

icetana - Change of CEO and Chair (ASX:ICE)

Highlights: icetana appoints current Chief Operating Officer Kevin Brown as new Chief Executive Officer effective 1 August 2023. To support continuity, Matt Macfarlane is appointe...read more

Immutep - Efti clinical data to be presented at ESMO Congress 2023 (ASX:IMM)

-- Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus KEYTRUDA® (pembrolizumab) -- Two additional posters on investi...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Late-stage & registrational trial progress: -- TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC) ...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - June 2023 (ASX:IIQ)

Highlights: -- Positive clinical data demonstrating SubB2M/CA15-3 test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) -- Post quarter ...read more

Immutep - 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial (ASX:IMM)

SYDNEY, AUSTRALIA – 28 July 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel L...read more

icetana - Quarterly Activities Report (ASX:ICE)

icetana Limited (ASX: ICE) (“icetana” or “the Company” or “we”), an AI software company providing artificial intelligence solutions to detect real-time anomalous ...read more

icetana - Quarterly Appendix 4C Cash Flow Report (ASX:ICE)

To view the appendix, download the attached PDF.

INOVIQ and Promega announce Global Joint Marketing Agreement (ASX:IIQ)

Melbourne, Australia and Madison, WI USA, 6 July 2023: INOVIQ Limited (ASX:IIQ) (INOVIQ), an innovative developer of exosome solutions and precision diagnostics, and Promega Corporation (Promega), a...read more

Viewing: 121 - 135 of 200 Previous | Next